Memantine, a drug developed by Merz back in the 1960s, had been on the market in Germany even before September 1 1976, when it was authorised on the basis of Article 3(7) of the AMG 1976 on the basis of transitional arrangements, provided for under the national legislation transposing Directive 65/65, which exempted medicinal products already on the market from the application of the Community authorisation procedure for a period of 12 years. This old German transitional authorisation expired on January 1 1990, although Merz remained on the German market until July 9 2002.